CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Advanced Non-Clear Cell Renal Cell Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04413123
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:35.392745+00:00
Published At: 2026-01-21T00:00:00+00:00
Record Updated At: 2026-01-21
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Papillary Renal Cell Carcinoma", "Unclassified Renal Cell Carcinoma", "Translocation Renal Cell Carcinoma", "Chromophobe Renal Cell Carcinoma", "Collecting Duct Renal Cell Carcinoma", "Renal Cell Carcinoma", "Unresectable Advanced Renal Cell Carcinoma", "Metastatic Ncc Renal Cell Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-21"
protocolSection.identificationModule.nctId: "NCT04413123"
protocolSection.identificationModule.officialTitle: "A Phase 2 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Advanced Non-Clear Cell Renal Cell Carcinoma"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.